drugset

drugset / Trial / NCT05712083

A Study of BCMA CAR-T Cell Therapy for Newly Diagnosed Multiple Myeloma

NCT05712083 ↗

Phase 2 Unknown 40 enrolled Zhejiang University Yake Biotechnology Ltd. · collab

NaSingle-groupOpen-labelTreatment

Summary

Clinical Trial for the Safety and Efficacy of BCMA CAR-T Cell Therapy for Newly Diagnosed Multiple Myeloma

Timeline

Start: 2023-01-30
Primary completion: 2024-04-01
Completion: 2024-04-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BCMA CAR-T cells	Cell therapy	—	Intravenous

Indications